Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG
- 20 April 2016
- journal article
- editorial
- Published by Elsevier in Clinical Therapeutics
- Vol. 38 (6) , 1279-1287
- https://doi.org/10.1016/j.clinthera.2016.03.035
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Long-Term Effects of Intensive Glucose Lowering on Cardiovascular OutcomesNew England Journal of Medicine, 2011
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 DiabetesNew England Journal of Medicine, 2005
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialPublished by Elsevier ,2005
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Long-Term Glycemic Control Relates to Mortality in Type II DiabetesDiabetes Care, 1995
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993
- CORONARY THROMBOSIS AND MYOCARDIAL INFARCTION, WITH GLYCOSURIABMJ, 1931
- CORONARY THROMBOSISMedicine, 1929